Instalab
logoInstalab

Acetylcholine Receptor Ganglionic Antibody

Blood Test
Check whether severe blood pressure drops and gut slowing may share an immune cause.
4.9 (4,683 reviews)
Tested by Quest Diagnostics
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a Acetylcholine Receptor Ganglionic Antibody test?

This test is most useful if any of these apply to you.

Having Severe Dizziness When You Stand
May help identify an immune cause when blood pressure drops occur with other signs of autonomic failure.
Dealing With Severe Gut Motility Problems
Can support an immune evaluation for severe, unexplained gut slowing, especially when other autonomic functions are affected.
Living With Sjögren's or Lupus
May add evidence when you develop symptoms or test findings suggesting autonomic nerve involvement.
Living With Unexplained Autonomic Symptoms
Loss of sweating, bladder-emptying trouble, and abnormal pupil responses can support a targeted evaluation for AAG.

About Acetylcholine Receptor Ganglionic Antibody

A large blood pressure drop when you stand, severe slowing of digestion, and loss of sweating can occur together when your autonomic nervous system is failing. An immune attack on the nerve relay stations is one possible cause. This antibody can help identify it, especially when several automatic functions are affected.

Ganglionic acetylcholine receptor antibody testing is an established diagnostic aid for suspected autoimmune autonomic ganglionopathy. Its usefulness depends on the symptoms and examination findings that led to testing. An isolated positive result carries much less weight.

Relay Stations for Your Automatic Nerves

The autonomic nervous system helps regulate blood pressure, heart rate, digestion, bladder emptying, sweating, and pupil size. Many of its signals pass through clusters of nerve cells called ganglia. At these relay stations, acetylcholine carries a signal from one nerve cell to receptors on the next.

Ganglionic AChR antibodies bind receptors containing a piece called the alpha-3 subunit. Experiments with antibodies purified from the blood of people with AAG show that they can reduce receptor function in cultured nerve cells. Other cell experiments show loss of receptors from the cell surface. These laboratory findings help explain how the antibodies can interrupt nerve signaling.

This test measures receptor-binding antibodies in serum using radioimmunoprecipitation. Serum is the liquid left after blood clots. The assay measures binding to receptors extracted from cells; it does not directly measure the antibody's effect on living nerves. Autonomic function tests provide that clinical context.

Autoimmune Autonomic Ganglionopathy

Autoimmune autonomic ganglionopathy is usually shortened to AAG. It can develop quickly or progress more slowly, and it can disrupt several automatic functions at once. Common features include:

  • Blood pressure: a large drop when you stand, causing lightheadedness or fainting.
  • Digestion: impaired movement of food through the digestive tract, with early fullness, nausea, bloating, or constipation.
  • Sweating and bladder: reduced sweating and difficulty emptying the bladder.
  • Eyes and mouth: pupils that respond poorly to light, reduced tears, and dry mouth.

Other illnesses can coexist with AAG. A Japanese study of 179 people who tested positive using a research assay for alpha-3 and beta-4 receptor antibodies also reported sensory symptoms, brain-related symptoms, hormone disorders, other autoimmune diseases, and tumors. That assay differs from this receptor-binding test, and the findings do not establish that this antibody caused every accompanying problem.

What Your Level Adds

Higher antibody levels are more strongly associated with severe autonomic failure, but the relationship has exceptions. Some people with substantial autonomic impairment have low levels, and some with high levels have little impairment.

Who Was StudiedWhat Was ExaminedWhat They Found
157 people with various autonomic disorders, plus control groupsSerum receptor-binding antibodies in different clinical groupsAntibodies were found in 41% of the 46 people with unexplained or cancer-associated autonomic neuropathy. None of 133 healthy controls tested positive, though some people with other autonomic disorders did.
289 antibody-positive people with autonomic testingAntibody level and measured autonomic impairmentHigher levels were more closely associated with severe failure. Low levels did not reliably distinguish people with autonomic failure from those without it.
95 antibody-positive people at a neurology referral centerHow often a positive result accompanied AAGOnly 22% had AAG. Their median antibody level was about twice that of people without autonomic manifestations.

A substantial result together with a matching pattern of autonomic failure strongly supports an immune cause. A negative result still leaves room for AAG: the standard antibody assay detects only about half of clinically diagnosed acute or subacute cases.

Findings in Other Conditions

Low-level receptor-binding antibodies have been found in people with celiac disease or lupus who lacked clear autonomic failure. Their presence may reflect a broader autoimmune response, but a positive result alone cannot establish why you have symptoms.

Several Japanese studies examined serum antibodies to the alpha-3 and beta-4 receptor pieces separately using a research method called LIPS. Its measurements and positivity rates are not interchangeable with this radioimmunoprecipitation test. Those studies reported the following associations:

  • Sjögren's syndrome: antibodies were detected in 23% of 39 people in one cohort. In a separate, selected group with autonomic symptoms, 8 of 10 tested positive.
  • Gut motility disorders: antibodies were detected in about a fifth of a small achalasia group and half of a small group with chronic intestinal pseudo-obstruction. Achalasia interferes with relaxation of the lower esophagus during swallowing. Chronic intestinal pseudo-obstruction causes symptoms of a blockage without a physical obstruction.
  • Systemic sclerosis: in a study of 50 people, alpha-3 antibody levels were higher in those with digestive involvement.
  • Autoimmune hepatitis: antibodies to alpha-3 or beta-4 were detected in 11.5% of 260 people.
  • Neurosarcoidosis: a small case series found alpha-3 and/or beta-4 antibodies in people with severe autonomic dysfunction. Whether the antibodies contributed to their illness remains uncertain.

These findings support investigating immune mechanisms in some autonomic and digestive disorders. They do not establish these assays as general screening tests for those conditions or prove that an antibody-positive person will benefit from immune treatment.

Cancer Links

Some cases of AAG occur as part of a cancer-associated immune response. Reported tumors include lung cancer and thymoma. A thymoma develops in the thymus gland in the chest.

The antibody alone is a limited cancer predictor. In the 95-person referral cohort, only two new cancers were diagnosed after antibody detection. Cancer risk assessment therefore depends on the neurological syndrome, other antibody findings, medical history, and symptoms. A low positive by itself does not justify an extensive cancer search.

When Results Can Be Misleading

  • Low-level binding without disease: radioimmunoprecipitation can detect antibody binding that has uncertain clinical significance. A positive result does not by itself demonstrate an active attack on your autonomic nerves.
  • Healthy people can test positive: later studies have found low-level antibodies in healthy controls, despite the absence of positives in the original control group.
  • Excess antibody proteins: unusually high amounts of one or several types of antibody protein can produce false low positives with this assay.
  • Treatment before collection: plasma exchange and immune treatment can lower antibody levels, so a result obtained during treatment may differ from an untreated baseline.
  • Radioactive tracers: recent nuclear medicine procedures can interfere with a radioimmunoprecipitation assay. Collection timing matters after these procedures.
  • Similar test names: muscle acetylcholine receptor antibodies and ganglionic receptor antibodies target different receptors. A muscle antibody result cannot substitute for this one.
  • A negative result: clinically significant autoimmune autonomic disease can occur without detectable ganglionic receptor antibodies.

Tracking Your Trend

Antibody changes sometimes accompany recovery, but they can also diverge from symptoms. In a three-person conference report, two people had rising levels after immune treatment was withdrawn without a return of severe autonomic failure, although some bowel, bladder, and pupil abnormalities remained or increased. A later UK study with long-term follow-up found that antibody levels reflected impairment at disease onset better than changes during follow-up. Symptoms and measured autonomic function remain central to treatment decisions.

What Moves This Biomarker

Evidence-backed interventions that affect your Acetylcholine Receptor Ganglionic Antibody level

↓ Decrease
Combination immunotherapy using intravenous immunoglobulin, corticosteroids, and other immune-suppressing medicines
Small uncontrolled studies report substantial antibody reductions and improvements in autonomic function during treatment. In a UK cohort, the post-treatment group median antibody level was about 72% lower than the pretreatment median. This compares group medians, not the average change in each person. Standing tolerance and pupil responses also improved, but residual impairment and relapses remained common.
MedicationStrong Evidence
↓ Decrease
Therapeutic plasma exchange
Plasma exchange removes circulating antibodies and can substantially lower the measured level. In a published case of severe autoimmune autonomic failure, antibody removal was followed by marked improvement in autonomic function. Small clinical cohorts also report benefit, but it can be temporary because antibody production continues. Repeat treatment or additional immune therapy may be needed.
ProcedureStrong Evidence

Frequently Asked Questions

References

25 studies
  1. Steven Vernino, Phillip a. Low, Robert D. Fealey, John D. Stewart, Gianrico Farrugia, Vanda a. LennonNew England Journal of Medicine2000
  2. Jeremy K. Cutsforth-gregory, Andrew Mckeon, Elizabeth a. Coon, David M. Sletten, Mariana Suarez, Paola Sandroni, Wolfgang Singer, Eduardo E. Benarroch, Robert D. Fealey, Phillip a. LowMayo Clinic Proceedings2018
  3. Yuebing Li, Adham Jammoul, Karin Mente, Jianbo Li, Robert W. Shields, Steven Vernino, Alexander Rae-grantMuscle & Nerve2015
  4. Steven Vernino, Jon Lindstrom, Steve Hopkins, Zhengbei Wang, Phillip a. Low, Muscle Study GroupJournal of Neuroimmunology2008
  5. Zhengbei Wang, Phillip a. Low, Jens Jordan, Roy Freeman, Christopher H. Gibbons, Christoph Schroeder, Paola Sandroni, Steven VerninoNeurology2007

Acetylcholine Receptor Ganglionic Antibody Test

$899
FSA/HSA eligible
No Rx needed
HIPAA compliant